LAS VEGAS, April 15, 2019 (GLOBE NEWSWIRE) --
CV Sciences,
Inc. (CVSI) (the “Companyâ€, “CV
Sciencesâ€, “ourâ€, “us†or “weâ€), a preeminent supplier and
manufacturer of hemp CBD products, announced that it has appointed
Deloitte & Touche LLP (“Deloitteâ€) as the Company’s new
independent registered public accounting firm.
“Following a thorough selection process, the Company’s Audit Committee has concluded that Deloitte is best positioned to meet the evolving needs of CV Sciences. We would like to thank Tanner LLC for the quality work and expertise they have provided over the last three years,†said Joseph Dowling, Chief Executive Officer of CV Sciences.
The Company has also filed a Form 8-K with the Securities and Exchange Commission noting the engagement of Deloitte.
About CV Sciences, Inc.
CV Sciences, Inc. (CVSI) operates two
distinct business segments: a consumer product division focused on
manufacturing, marketing and selling plant-based CBD products to a
range of market sectors; and a drug development division focused on
developing and commercializing CBD-based novel therapeutics
utilizing synthetic CBD. The Company’s PlusCBD Oil™ is the
top-selling brand of hemp-derived CBD on the market, according to
SPINS, the leading provider of syndicated data and insights for the
natural, organic and specialty products industry. CV Sciences, Inc.
has primary offices and facilities in San Diego, California and Las
Vegas, Nevada. Additional information is available from
OTCMarkets.com or by visiting www.cvsciences.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking
statements and information, as defined within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, and is subject to the Safe Harbor
created by those sections. This material contains statements about
expected future events and/or financial results that are
forward-looking in nature and subject to risks and uncertainties.
Such forward-looking statements by definition involve risks,
uncertainties.
CONTACT INFORMATION:
Investor Contact:
ICR
Scott Van Winkle
617-956-6736
[email protected]
Media Contact:
ICR
Cory Ziskind
646-277-1232
[email protected]